Korean J Gastroenterol.  2023 Mar;81(3):142-144. 10.4166/kjg.2023.025.

The Impact of Cancer Treatments on the Disease Activity of Inflammatory Bowel Diseases

• Jeon SR

• KMID: 2540959
• DOI: http://doi.org/10.4166/kjg.2023.025

Reference

1. Korean Association for the Study of Intestinal Diseases. 2020. 2020 Inflammatory bowel disease fact sheet in Korea [Internet]. Korean Association for the Study of Intestinal Diseases, 2020;Seoul: cited 2022 Jul 11. Available from: http://m.kasid.org/file/IBM/IBD%20fact%20sheet_1217.pdf.

2. Lo B, Zhao M, Vind I, Burisch J. 2021; The risk of extraintestinal cancer in inflammatory bowel disease: a systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 19:1117–1138.e19. DOI: 10.1016/j.cgh.2020.08.015. PMID: 32801010.

3. Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M. 2012; Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 143:375–381.e1. quiz e13-4DOI: 10.1053/j.gastro.2012.04.016. PMID: 22522090.

4. Attauabi M, Zhao M, Bendtsen F, Burisch J. 2021; Systematic review with meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease course of inflammatory bowel diseases. Inflamm Bowel Dis. 27:927–939. DOI: 10.1093/ibd/izaa167. PMID: 32628745.

5. Sougiannis AT, VanderVeen BN, Davis JM, Fan D, Murphy EA. 2021; Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience. Am J Physiol Gastrointest Liver Physiol. 320:G712–G719. DOI: 10.1152/ajpgi.00380.2020. PMID: 33471628. PMCID: PMC8202195.

6. Weingarden AR, Rubin SJS, Gubatan J. 2021; Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World J Gastrointest Oncol. 13:772–798. DOI: 10.4251/wjgo.v13.i8.772. PMID: 34457186. PMCID: PMC8371513.

7. Grimsdottir S, Attauabi M, Dahl EK, Burisch J, Seidelin JB. Systematic review with meta-analysis: The impact of cancer treatments on the disease activity of inflammatory bowel diseases. J Crohns Colitis. 2023; Jan. 22. doi: 10.1093/ecco-jcc/jjad010. DOI: 10.1093/ecco-jcc/jjad010. PMID: 36682029.

8. Gordon H, Biancone L, Fiorino G, et al. ECCO Guidelines on inflammatory bowel disease and malignancies. J Crohns Colitis. 2022; Dec. 18. doi: 10.1093/ecco-jcc/jjac187. DOI: 10.1093/ecco-jcc/jjac187. PMID: 36528797.

9. Cantrell JN, Vidal GS, Bitar H, Ahmad S, Gunter TC. 2020; Should inflammatory bowel disease be a contraindication to radiation therapy: a systematic review of acute and late toxicities. J Radiother Pract. 20:480–489. DOI: 10.1017/S1460396920000783.

10. Axelrad JE, Fowler SA, Friedman S, Ananthakrishnan AN, Yajnik V. 2012; Effects of cancer treatment on inflammatory bowel disease remission and reactivation. Clin Gastroenterol Hepatol. 10:1021–1027.e1. DOI: 10.1016/j.cgh.2012.06.016. PMID: 22732273.

11. Axelrad JE, Bazarbashi A, Zhou J, et al. New York Crohn's and Colitis Organization. Hormone therapy for cancer is a risk factor for relapse of inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020; 18:872–880.e1. DOI: 10.1016/j.cgh.2019.06.042. PMID: 31302306. PMCID: PMC7354097.

12. Meserve J, Facciorusso A, Holmer AK, Annese V, Sandborn WJ, Singh S. 2021; Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. Aliment Pharmacol Ther. 53:374–382.

13. Tran AN, Wang M, Hundt M, et al. 2021; Immune checkpoint inhibitor-associated diarrhea and colitis: a systematic review and meta-analysis of observational studies. J Immunother. 44:325–334. DOI: 10.1097/CJI.0000000000000383. PMID: 34380976.

14. Amiot A, Laharie D, Malamut G, Serrero M, Poullenot F. educational committee of the GETAID. 2022; Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID. Dig Liver Dis. 54:1162–1167. DOI: 10.1016/j.dld.2022.06.020. PMID: 35842365.

15. Kirk PS, Govani S, Borza T, et al. 2017; Implications of prostate cancer treatment in men with inflammatory bowel disease. Urology. 104:131–136. DOI: 10.1016/j.urology.2017.01.030. PMID: 28163082. PMCID: PMC5520802.